GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials
| Autor: | Anna Maria Testi, Andrea Pession, Franco Mandelli, Nicola Santoro, Giuseppe Menna, Maria Luisa Moleti, Giuseppe Fioritoni, Marco Vignetti, Andrea Biondi, Franco Locatelli, Carmelo Rizzari, Daniela Diverio, Robin Foà, Riccardo Masetti, Francesco Lo Coco, Giuseppe Basso, Gabriella Tomei |
|---|---|
| Přispěvatelé: | A. M. Testi, R. Foa, G. Tomei, F. L. Coco, A. Biondi, A. Pession, D. Diverio, M. Vignetti, G. Basso, F. Locatelli, C. Rizzari, G. Menna, M. L. Moleti, N. Santoro, G. Fioritoni, R. Masetti, F. Mandelli |
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Acute promyelocytic leukemia
medicine.medical_specialty Anthracycline business.industry Immunology pediatric acute myeloid leukemia Cell Biology Hematology Newly diagnosed acute promyelocitic leukemia medicine.disease Biochemistry Regimen Acute promyelocytic leukemia apl Internal medicine Cytarabine medicine Idarubicin Methotrexate business medicine.drug |
| Popis: | Abstract 871 Since 1993, Italian pediatric patients (age The 6-year Kaplan-Meier estimates of overall survival (OS) and disease-free survival (DFS) are 89.7% (CI 95%: 84.7–95) vs 96% (CI 95%: 91.7–100), (p 0.05) and 73.1% (CI 95%: 66.7–80.2) vs 82.5% (CI 95%: 75.9–89.8), (p 0.28) in the AIDA 0493 and 2000 protocols, respectively. For low/intermediate risk children, OS and DFS at 6 years are 94.2% (CI 95%: 89.1–99.5) and 76.7% (CI 95%: 68.9–85.4) in the AIDA 0493 vs 95.6% (CI 95%: 90.0–100) and 82.7% (CI 95% 74.9–91.3) in the AIDA 2000 trial, respectively (p 0.57 and 0.73); considering high risk patients, OS and DFS at 6 years are 81.6% (CI 95%: 72.1–92.3) and 65.2% (CI 95%: 54.7–77.6) in the AIDA 0493 vs 96.8% (CI 95%: 90.9–100) and 82.3% (CI 95%: 70.1–96.5) in the AIDA 2000 trial (p 0.05 and 0.20). These results confirm the high anti-leukemic efficacy of the ATRA + idarubicin induction combination. For low/intermediate risk children, the anthracycline-based plus ATRA consolidation is equally effective as the previous cytarabine-containing regimen. The risk-adapted strategy including ATRA for consolidation resulted into a significant improvement in OS for all children. Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group. Disclosures: Foa: Roche: Consultancy, Speakers Bureau. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|